|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | DNA polymorphism of HLA class II genes in primary biliary cirrhosis显示文摘 | Niels Morling Kim Dalhoff Lars Fugger J?rgen Georgsen Bodil Jakobsen Leo Ranek Niels ?dum Arne Svejgaard | 1992 | Immunogenetics1992，，2： | 2 |
| 2 | Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects 显示文摘 | Stass H Dalhoff A Kubitza D | 1998 | Antimicrob Agents Chemother1998，42，8： | 1 |
| 3 | Drug-drug interactions among recently hospitalised patients - frequent but mostly clinically insignificant显示文摘 | Glintborg B Andersen SE Dalhoff K | 2005 | Eur J Ulin Pharmacol2005，61，9： | 1 |
| 4 | Approaches to estimate the population-based incidence of community acquired pneumonia显示文摘 | Maike Schnoor Jens Hedicke Klaus Dalhoff | 2007 | Journal of Infection2007，55，3： | 1 |
| 5 | Global Fluoroquinolone Resistance Epidemiology and Implictions for Clinical Use显示文摘 | Axel Dalhoff Abiola C. Senok | 2012 | <journal-title>Interdisciplinary Perspectives on Infectious Diseases2012，，： | 1 |
| 6 | Pharmacokinetics, safety,and tolerbility of ascending single doses of Moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects显示文摘 | Stass H Dalhoff A Kubitza D | 1998 | Antimicrob Agents Chemothe1998，42，8： | 1 |
| 7 | Cytochrome P450 polymorphism and postoperative cognitive dysfunction显示文摘 | Steinmetz J Jespersgaard C Dalhoff K | 2012 | Minerva anestesiologica2012，78，3： | 1 |
| 8 | Pharmacokinetics, safety, and tolerability of ascending singledoses of moxifloxacin, a new 8-rnethoxyquinolone, administered to healthy subjects显示文摘 | Stass H Dalhoff A Kubitza D | 1998 | 42(8): 2060-20651998，42，8： | 1 |
| 9 | The asso- ciation of reduced folate carrier 80G > A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromo- some 21 copy number显示文摘 | GREGERS J CHRISTENSEN I J DALHOFF K | 2010 | Blood2010，115，23： | 1 |
| 10 | Hydroxymethylglutaryl coenzyme A reductase inhibitors modify inflammatory response of human macrophages and endothelial cells infected with chlamydia pneumoniae显示文摘 | Dalhoff K Rupp J | 2000 | Circulation2000，101，： | 1 |
| 11 | HMG-CoA reductase inhibitors modify the in flammatory response of human macrophage and endothelial cells infected with chlamydia pneumoniae显示文摘 | Kothe H Dalhoff K Rupp J | 2000 | Circulation2000，101，： | 1 |
| 12 | Redefining penems显示文摘 | Dalhoff A Janjic N Echols R | 2006 | Biochem Pharmacol2006，71，7： | 1 |
| 13 | Beta-lactamase stability of faropenem显示文摘 | Dalhoff A Nasu T Okamoto K | 2003 | Chemotherapy2003，49，： | 1 |
| 14 | Hydroxymethylglutary coenzyme A reductase inhihitors modify the inflammatory response of human macrophages and endothelial cells infected with chlamydia pneumoniae 显示文摘 | Kothe H Dalhoff K Rupp J | 2000 | Circulation2000，101，： | 1 |
| 15 | Beta - lactamase stability of faro- penem 显示文摘 | Dalhoff A Nasu T Okamoto K | 2003 | Chemotherapy2003，49，： | 1 |
| 16 | Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae显示文摘 | Kothe H Dalhoff K Rupp J | 2000 | Circulation2000，101，15： | 1 |
| 17 | Pharmacokinetics,Safety,and Tolerability of Ascending Single Doses of Moxifloxacin,a New 8-Methoxy Quinolone,Administered to Healthy Subjects显示文摘 | Stass H Dalhoff A Kubitua D | 1998 | Antimicrob Agents Chemother1998，42，8： | 1 |
| 18 | Hypdorxymethylglutaryl coenzyme A reduced inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with chlamydia pneumoniae显示文摘 | Kothe H Dalhoff K Rupp J | 2000 | Circulation2000，，10： | 1 |
| 19 | Acute versus chronicalcohol consumption in acetaminophen induced hepatotoxicity 显示文摘 | Schmidt LE Dalhoff K Poulsen HE | 2002 | Hepatology2002，35，9： | 1 |
| 20 | Hypdorxymethylglutaryl coenzyme A reduced inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with chlamydia pneumoniae显示文摘 | Kothe H Dalhoff K Rupp J | 2000 | Circulation2000，，101： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员